FDA panel votes unanimously to make birth control pill available over the counter


The U.S. Food and Drug Administration's advisory panel voted unanimously to make the birth control pill Opill available over the counter, saying that the benefits outweigh the risks, The New York Times reports. "I think Opill has the potential to have a huge positive public health impact," said advisory committee member Kathryn Curtis.
While Opill manufacturer Perrigo called the outcome "groundbreaking," this doesn't mean the pill will be available just yet, CNN writes. The FDA is not required to listen to the advisory committee and will decide whether to make the pill available sometime in the summer. Some agency members are concerned about whether people will use the product as directed, especially those with health conditions and adolescents. "The FDA has been put in a very difficult position of trying to determine whether it is likely that women will use this product safely and effectively at the nonprescription setting," explained Dr. Karen Murry, deputy director of the FDA's office of nonprescription drugs.
The push to approve Opill is stronger than ever as many states have adopted extra-restrictive abortion bans following the overturning of Roe v. Wade (1973). Maternal healthcare has also reportedly been on a decline because of these laws. "I think this represents a landmark in our history of women's health," commented advisor Dr. Marjorie Gass said of the FDA progress. "Unwanted pregnancies can really derail a woman's life, and especially an adolescent's life."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We are motivated by the millions of people who need easy access to safe and effective contraception," remarked Perrigo president and CEO Murray S. Kessler in a statement. "Today's outcome reflects Perrigo's steadfast commitment to women and people, and their health."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Gavin Newsom mulls California redistricting to counter Texas gerrymandering
TALKING POINTS A controversial plan has become a major flashpoint among Democrats struggling for traction in the Trump era
-
6 perfect gifts for travel lovers
The Week Recommends The best trip is the one that lives on and on
-
How can you get the maximum Social Security retirement benefit?
the explainer These steps can help boost the Social Security amount you receive
-
Children's health has declined in the US
The Explainer It's likely a sign of larger systemic issues
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Is that the buzzing sound of climate change worsening sleep apnea?
Under the radar Catching diseases, not those ever-essential Zzs
-
Deadly fungus tied to a pharaoh's tomb may help fight cancer
Under the radar A once fearsome curse could be a blessing
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Climate change can impact our gut health
Under the radar The gastrointestinal system is being gutted
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
Orthorexia nervosa: when clean eating goes too far
The Explainer Being healthy is fine, but obsessing over it is dangerous